Just about everything that has been announced is simultaneously intriguing and baffling. For example, earlier this week I read that the Secretary of Iran's Nanotechnology Initiative Council, Saeed Sarkar, was claiming that Iran was ranked 12th in the world for production of nanoscience.
Now I have no reason not to believe that claim, mainly because I am not sure I could name off the top of my head who is ranked 1 through 11, but more important, I am not sure what it means.
Could it be the production of scientific papers with reference to nanotechnology? We now know that the pursuit of this metric is often on a slippery slope. Or could it be funding? Hard to say on that one; Iran’s expenditures on nanotechnology are not as well known as some other countries. And translating funding into actual impact is probably more critical than just the amount allocated.
The main problem in ranking Iran’s place in the nanotechnology hierarchy is that of transparency: We just don’t know that much.
One of the few people I know who has visited Iran with the purpose of working on nanotechnology is Tim Harper, who offered this about Iran during an interview with Frogheart back in July:
“Iran is a different case, and it’s a place I have visited several times to discuss nanotechnologies. While the world may have some issues with the Iranian government, the scientists and business people I deal with are just like the rest of us. Iran has some great science going on, and the U.S. embargo has meant that they have had to be quite ingenious to get access to even basic instrumentation such as electron microscopes. However, there’s a large domestic market, and the Iranians are manufacturing everything from scientific instruments to nanomaterials. When the political issues are solved, I think a few people will be surprised by the level of sophistication of Iranian nanoscience.”
I suppose Harper’s view is all I really have to prevent me from considering with skepticism recent claims that researchers in Iran have developed a form of the cancer drug doxorubicin that has eliminated many of the drug’s side effects. The new formulation may be a great breakthrough, but I am not sure whether its presentation as a “cure for cancer” is just your typical run-of-the-mill hype or state-sponsored propaganda.In either case, I wish the Iranians would avoid that kind of announcement, especially when their entire nanotechnology enterprise remains a mystery for many. Sanctions or no, science needs transparency to progress, both within and outside Iran.